Primed for global coronavirus pandemic: Emerging research and clinical outcome

Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV

(2020) Jared S. Morse et al.   CHEMBIOCHEM

Discovery and development of safe-in-man broad-spectrum antiviral agents

(2020) Petter I. Andersen et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore

(2020) Barnaby Edward Young et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

(2020) Guangdi Li et al.   NATURE REVIEWS DRUG DISCOVERY

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

(2020) Daniel Wrapp et al.   SCIENCE

Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential

(2020) Jimin Xu et al.   ACS Infectious Diseases

Old Weapon for New Enemy: Drug Repurposing for Treatment of Newly Emerging Viral Diseases

(2020) Deyin Guo   VIROLOGICA SINICA

Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs

(2020) Sangeun Jeon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The epidemiology, diagnosis and treatment of COVID-19

(2020) Pan Zhai et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Teicoplanin: an alternative drug for the treatment of COVID-19?

(2020) Sophie Alexandra Baron et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

(2020) Philippe Gautret et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Lack of Antiviral Activity of Darunavir against SARS-CoV-2

(2020) Sandra De Meyer et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

A Review of SARS-CoV-2 and the Ongoing Clinical Trials

(2020) Yung-Fang Tu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)

(2020) James M. Sanders et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The convalescent sera option for containing COVID-19

(2020) Arturo Casadevall et al.   JOURNAL OF CLINICAL INVESTIGATION

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

(2020) Ivan Fan-Ngai Hung et al.   LANCET

Remdesivir for the Treatment of Covid-19 — Preliminary Report

(2020) John H. Beigel et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

(2020) Bin Cao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

(2020) Joshua Geleris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019

(2020) Ashley Barlow et al.   PHARMACOTHERAPY

Effective treatment of severe COVID-19 patients with tocilizumab

(2020) Xiaoling Xu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Development of an inactivated vaccine candidate for SARS-CoV-2

(2020) Qiang Gao et al.   SCIENCE

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

(2020) Timothy P. Sheahan et al.   Science Translational Medicine

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

(2020) Xiuyuan Ou et al.   Nature Communications

The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses

(2020) Longping V. Tse et al.   Frontiers in Microbiology

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

(2020) Qingxian Cai et al.   Engineering

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

(2020) Leon Caly et al.   ANTIVIRAL RESEARCH

Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study

(2020) Abdo A. Elfiky   LIFE SCIENCES

Ongoing Clinical Trials for the Management of the COVID-19 Pandemic

(2020) Mark P. Lythgoe et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells

(2020) Hussin A. Rothan et al.   VIROLOGY

Covid-19: Demand for dexamethasone surges as RECOVERY trial publishes preprint

(2020) Elisabeth Mahase   BMJ-British Medical Journal

Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis

(2020) Andreas Muehler et al.   Multiple Sclerosis and Related Disorders

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

(2020) Alexandra C. Walls et al.   CELL

Addendum: A pneumonia outbreak associated with a new coronavirus of probable bat origin

(2020) Peng Zhou et al.   NATURE

Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion

(2019) Alexandra C. Walls et al.   CELL

SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection

(2019) Nils C. Gassen et al.   Nature Communications

Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol

(2016) Rameshwar U. Kadam et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses

(2016) Shuo Su et al.   TRENDS IN MICROBIOLOGY

Auranofin: Repurposing an Old Drug for a Golden New Age

(2015) Christine Roder et al.   Drugs in research & development

Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases

(2013) Lars Petter Jordheim et al.   NATURE REVIEWS DRUG DISCOVERY